Blueprint Medicines has claimed its second FDA approval for Ayvakit, getting the nod for advanced systemic mastocytosis (SM), a group of rare blood cancers currently treated mainly by Novar
Our website has served us well over the years, but after five years since the last re-design – during which aesthetic standards have changed and website technology has improved
